Puma Biotechnology, Inc. (PBYI) — SEC Filings
Puma Biotechnology, Inc. (PBYI) — 27 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 10 8-K, 5 10-Q, 4 SC 13G/A.
View Puma Biotechnology, Inc. on SEC EDGAR
Overview
Puma Biotechnology, Inc. (PBYI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Puma Biotechnology, Inc. reported a significant decrease in net income for the three months ended September 30, 2025, falling to $8.844 million from $20.317 million in the prior year, a 56.4% decline. This was primarily driven by a sharp drop in royalty revenue, which decreased from $24.406 million
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 21 neutral. The dominant filing sentiment for Puma Biotechnology, Inc. is neutral.
Filing Type Overview
Puma Biotechnology, Inc. (PBYI) has filed 5 10-Q, 1 10-Q/A, 10 8-K, 1 DEF 14A, 2 10-K, 3 SC 13G, 1 DEFA14A, 4 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of PBYI's 19 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $54,475,000 |
| Net Income | $8,844,000 |
| Cash Position | $53,525,000 |
| Operating Margin | 17.6% |
| Total Assets | $202,862,000 |
| Total Debt | $33,716,000 |
Key Executives
- Allison Dorval
- Alessandra Cesano
- Jay Moyes
- Adrian Senderowicz
- Brian Stuglik
- Douglas Hunt
- Jeff J. Ludwig
- Alvin Wong
- Maximo F. Nougues
- Alan H. Auerbach
- Dr. Jeffrey Handwerker
- Ms. Jennifer Simpson
Industry Context
The oncology market is characterized by intense competition, rapid scientific advancement, and significant regulatory hurdles. Companies like Puma Biotechnology focus on developing targeted therapies for specific cancer types, often requiring substantial R&D investment and facing challenges in clinical trials and market access. The success of a single drug can be critical, but diversification through pipeline development is also a common strategy.
Top Tags
earnings (3) · regulatory-filing (3) · Biotechnology (2) · corporate-governance (2) · compensation (2) · biotech (2) · loss (2) · proxy-statement (2) · financials (2) · 10-Q (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income (Q3 2025) | $8.844M | 56.4% decrease from $20.317M in Q3 2024 |
| Royalty Revenue (Q3 2025) | $2.573M | Significant drop from $24.406M in Q3 2024 |
| Total Revenue (Q3 2025) | $54.475M | 32.3% decrease from $80.542M in Q3 2024 |
| Net Income (9 Months 2025) | $17.673M | 61.1% increase from $10.973M in 9 Months 2024 |
| Product Revenue, Net (9 Months 2025) | $144.194M | Increased from $140.810M in 9 Months 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $53.525M | Decreased from $69.219M at Dec 31, 2024 |
| Alisertib Upfront License Fee | $7.0M | Paid to Takeda in October 2022 |
| Potential Alisertib Milestone Payments | $287.3M | Eligible to Takeda upon achievement of certain regulatory and commercial milestones |
| Shares Outstanding | 50,391,107 | As of November 3, 2025 |
| Cash, Cash Equivalents and Marketable Securities | $94.4M | Total at September 30, 2025 |
| Quarterly Period End Date | 2025-03-31 | The period covered by the 10-Q/A filing |
| Filed As Of Date | 2025-08-07 | Date the 10-Q/A was officially filed |
| Commission File Number | 001-35703 | Puma Biotechnology's SEC file number |
| Reporting Period | 12 months | Duration for which the registrant has filed all required reports |
| Fiscal Year End | 1231 | The company's fiscal year will now end on December 31st. |
Frequently Asked Questions
What are the latest SEC filings for Puma Biotechnology, Inc. (PBYI)?
Puma Biotechnology, Inc. has 27 recent SEC filings from Jan 2024 to Nov 2025, including 10 8-K, 5 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PBYI filings?
Across 27 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 21 neutral. The dominant sentiment is neutral.
Where can I find Puma Biotechnology, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Puma Biotechnology, Inc. (PBYI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Puma Biotechnology, Inc.?
Key financial highlights from Puma Biotechnology, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PBYI?
The investment thesis for PBYI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Puma Biotechnology, Inc.?
Key executives identified across Puma Biotechnology, Inc.'s filings include Allison Dorval, Alessandra Cesano, Jay Moyes, Adrian Senderowicz, Brian Stuglik and 7 others.
What are the main risk factors for Puma Biotechnology, Inc. stock?
Of PBYI's 19 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Puma Biotechnology, Inc.?
Forward guidance and predictions for Puma Biotechnology, Inc. are extracted from SEC filings as they are enriched.